The ATM offering provides near-term cash but at the cost of immediate dilution. Monitor the pace of share sales under the ATM — rapid issuance at current depressed prices (~$4.23) signals acute cash needs. The widening H1 loss and going-concern warnings suggest further capital raises are likely. The conflict-of-interest structure (director-led underwriter) may limit institutional appetite. Watch for any clinical trial catalysts from DiamiR's pipeline that could change the equity story.
Price Chart
Executive Summary
Niki BioSolutions filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $1,396,000 in common stock through H.C. Wainwright & Co. and Brookline Capital Markets. The offering is a takedown from the company's $75M universal shelf (S-3) filed in August 2026. The company has a going-concern opinion from its auditor, widening net losses, and a controlling shareholder (Dr. Kira Sheinerman, ~51.6% ownership) who is also a managing director at lead underwriter Wainwright, creating a FINRA Rule 5121 conflict of interest. The ATM program will dilute existing shareholders and signals ongoing cash needs for a clinical-stage life sciences company with no product revenue.
Key Facts
- ATM offering of up to $1,396,000 in common stock via H.C. Wainwright & Co. and Brookline Capital Markets
- 3.0% commission on gross proceeds to managers
- Dr. Kira Sheinerman, a director and ~51.6% shareholder, is a managing director at Wainwright — FINRA Rule 5121 conflict of interest with Brookline as qualified independent underwriter
- Company had net loss of $1,326,004 in H1 2026 vs $441,780 in H1 2025 (unaudited), a ~200% YoY increase
- Auditor's going-concern opinion on both Niki and its DiamiR subsidiary
- Net tangible book value per share would decrease from $5.24 to $5.12 post-offering, with $0.89 dilution per share to new investors at assumed $4.23 price
- Proceeds for general corporate purposes including working capital and product development
- Company has only 2 full-time employees and relies on outsourced R&D and back-office functions
- Principal operations in Hong Kong with PRC regulatory risk exposure
Financial Impact
Up to $1,396,000 gross proceeds from ATM offering; net loss widened to $1,326,004 in H1 2026 from $441,780 in H1 2025; net tangible book value per share decrease of $0.12 for existing shareholders and $0.89 dilution for new investors at assumed $4.23 price
Risk Factors
- Immediate and ongoing dilution from ATM sales at market prices
- Going-concern risk — auditor expressed substantial doubt; cash burn rate increasing
- Controlling shareholder (51.6%) and underwriter conflict may deter new investors
- No product revenue; clinical-stage pipeline with uncertain timelines
- PRC/Hong Kong regulatory and geopolitical risks could impair operations or listing status
- Low trading volume and concentrated ownership could amplify price volatility
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-108567 |
| Document: 0001213900-26-108567-index-headers.html | 0001213900-26-108567 |
| Document: 0001213900-26-108567-index.html | 0001213900-26-108567 |
| Document: 0001213900-26-108567.txt | 0001213900-26-108567 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 16d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 16d ago | 424B5 | — | awaiting T+1 | — | — |
Jul 20, 2026 14w ago | 8-K | $8.83 $9.54 | ▲ +8.04% | ▲ +7.21% | — |
Jul 16, 2026 14w ago | Press Release | $0.6924 $0.7000 | ▲ +1.10% | ▲ +2.09% | — |
Jun 10, 2026 19w ago | 6-K | $0.9038 $0.8900 | ▼ −1.53% | ▼ −3.23% | — |
Jun 4, 2026 20w ago | EFFECT | $1.09 $1.01 | ▼ −7.34% | ▼ −4.74% | — |
May 14, 2026 23w ago | 6-K | $0.8230 $0.8570 | ▼ −4.13% | ▼ −4.19% | — |
Mar 27, 2026 30w ago | 20-F | $0.8380 $0.7960 | ▲ +5.01% | ▲ +7.90% | — |
Mar 6, 2026 33w ago | Press Release | $0.8000 $0.7930 | ▲ +0.88% | ▲ +0.69% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers